Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317000 · ClinicalTrials.gov registry record · Phase 2
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
A Phase 2 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Barbara Burtness.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05317000 is a Phase 2 study of Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by Barbara Burtness. The registered enrollment target is 50 participants, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05317000, a Phase 2 study of Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by Barbara Burtness.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with nivolumab. 5-Azacytidine (5-AZA) is a chemotherapy, and nivolumab is an immunotherapy. Both drugs are approved for use in the US by the Food and Drug Administration (FDA) for use in the treatment of different types of cancer, and nivolumab is approved for use in head and neck cancer that has previously been treated with chemotherapy. Because they are not approved to be used together in HPV-associated head and neck cancer, these drugs are considered experimental in this study. For this study, the drugs will be used either together or separately.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG 5-azacytidine
- DRUG Combination 5-azacytidine and nivolumab
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05317000
The ClinicalTrials.gov registry entry for NCT05317000 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (70% lower). The listed sponsor is Barbara Burtness, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT05317000 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05317000 about?
NCT05317000 is a clinical study titled "5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC". This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with nivolumab. 5-Azacy...
What is the current status of trial NCT05317000?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2023-03-23. Estimated completion is 2028-11-30.
What conditions does trial NCT05317000 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.
What interventions are being tested in trial NCT05317000?
The interventions under investigation include: Nivolumab (DRUG), 5-azacytidine (DRUG), Combination 5-azacytidine and nivolumab (DRUG).
Who is sponsoring clinical trial NCT05317000?
This trial is sponsored by Barbara Burtness, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05317000 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
-
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RECRUITING · Phase 2
-
Pembrolizumab Plus Olaparib in LA-HNSCC
ACTIVE NOT RECRUITING · Phase 2
-
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.